Next Article in Journal
SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls
Previous Article in Journal
Side Effects Following Administration of the First Dose of Oxford-AstraZeneca’s Covishield Vaccine in Bangladesh: A Cross-Sectional Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Infectious Disease Reports
Volume 13
Issue 4
10.3390/idr13040081
idr-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Emerging Role of Neuropilin-1 and Angiotensin-Converting Enzyme-2 in Renal Carcinoma-Associated COVID-19 Pathogenesis

by
Md. Golzar Hossain
1,*,
Sharmin Akter
2 and
Md Jamal Uddin
3,4,*
1
Department of Microbiology and Hygiene, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
2
Department of Physiology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh
3
Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Korea
4
ABEx Bio-Research Center, East Azampur, Dhaka 1230, Bangladesh
*
Authors to whom correspondence should be addressed.
Infect. Dis. Rep. 2021, 13(4), 902-909; https://doi.org/10.3390/idr13040081
Submission received: 7 September 2021 / Revised: 14 October 2021 / Accepted: 15 October 2021 / Published: 16 October 2021
Browse Figures
Versions Notes

Abstract

Neuropilin-1 (NRP1) is a recently identified glycoprotein that is an important host factor for SARS-CoV-2 infection. On the other hand, angiotensin-converting enzyme-2 (ACE2) acts as a receptor for SARS-CoV-2. Additionally, both NRP1 and ACE2 express in the kidney and are associated with various renal diseases, including renal carcinoma. Therefore, the expression profiles of NRP1 and ACE2 in kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) patients from the various cancer databases were investigated along with their impact on patients’ survivability. In addition, coexpression analysis of genes involved in COVID-19, KIRC, and KIRP concerning NRP1 and ACE2 was performed. The results demonstrated that both t NRP1 and ACE2 expressions are upregulated in KIRC and KIRP compared to healthy conditions and are significantly correlated with the survivability rate of KIRC patients. A total of 128 COVID-19-associated genes are coexpressed, which are positively associated with NRP1 and ACE2 both in KIRC and KIRP. Therefore, it might be suggested that, along with the ACE2, high expression of the newly identified host factor NRP1 in renal carcinomas may play a vital role in the increased risk of SARS-CoV-2 infection and survivability of COVID-19 patients suffering from kidney cancers. The findings of this investigation will be helpful for further molecular studies and prevention and/or treatment strategies for COVID-19 patients associated with renal carcinomas.

1. Introduction

Neuropilin-1 (NRP1) is a multifaceted transmembrane glycoprotein that acts as a receptor for semaphorins (SEMA3A) and vascular endothelial growth factor (VEGF) family members [1,2]. Angiogenesis is believed to be influenced by NRP1 binding with VEGF-A, VEGF-B, VEGF-E, PlGF, and HGF/SF [3]. In addition, NRP1 also acts as a pro-angiogenic co-receptor by binding with the hepatocyte growth factor (HGF) in endothelial cells and enhancing the pro-angiogenic cytokines, VEGF-A, and HGF [3]. Moreover, VEGF plays a vital role in angiogenesis and generates tumor growth, tissue repair, and blood vessel networks. Therefore, VEGF and its receptors (VEGFR1 and VEGFR2, and NRP1) are targeted for treating cancer and vascular diseases [1]. Angiotensin-converting enzyme-2 (ACE2) is reported to be highly expressed in the proximal tubular cells of the kidney and regulates renal disease progression [4,5].
ACE2 is reported to be a receptor for SARS-CoV-2 in kidney injury, while, recently, NRP1 has been identified as a potential host factor for SARS-CoV-2, and NRP1 specifically binds with the C-end rule (CendR) motif of the S1 subunit of the spike protein [6,7]. Moreover, inhibiting this binding by monoclonal antibodies, small-molecule inhibitors, or RNA interference significantly reduced the SARS-CoV-2 entry in the cell culture, suggesting a potential therapeutic target for COVID-19 [6].
On the other hand, along with the lung, multiple organs such as the liver, kidneys, heart, and brain might be affected by SARS-CoV-2 in COVID-19 patients [8,9]. SARS-CoV-2 might cause acute kidney injury leading to increased hospital death of COVID-19 patients [10,11,12]. Importantly, a study revealed an increased incidence of SARS-CoV-2 infection in renal cell carcinoma patients with cancer progression and a higher mortality rate [13].
Therefore, in this study, we investigated the expression profile of NRP1 and ACE2 in kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) patients from various cancer databases. In addition, the relationship of NRP1 and ACE2 expression to patients’ survivability rate followed by the coexpression analysis of genes positively regulated with these factors and associated with COVID-19 were studied.

2. Materials and Methods

Gene Expression Profiling Interactive Analysis 2 (GEPIA2) server (http://gepia2.cancer-pku.cn/#index), a publicly accessible online database, was used to analyze the NRP1 expression profile across thirty-three (33) human cancers and paired normal tissues using the TCGA (The Cancer Genome Atlas) datasets [14]. Expression data of RNA sequencing of 9736 tumors and 8587 normal samples have been deposited in the GEPIA2, retrieved from the Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects. This web-based tool (GEPIA2) is designed to provide the various expression profiles of these tumors and normal tissues or cells in a customized manner according to multiple factors such as similar gene detection, pathological stages or cancer types, and patient survivability, etc. (http://gepia2.cancer-pku.cn/#index).
The mRNA expression profile of NRP1 and ACE2 in KIRC and KIRP patients are analyzed by the UALCAN website (http://ualcan.path.uab.edu/index.html) using the TCGA dataset [15]. There was a total of 605 samples in the case of KIRC, among which 72 and 533 were from controls (normal) and cancers (primary tumor), respectively. On the other hand, 32 and 290 were from controls (normal) and cancers (the primary tumor), respectively, in the case of KIRP. The survivability rate depending on NPR1 and ACE2 expressions in KIRC and KIRP was also analyzed using the UALCAN website (http://ualcan.path.uab.edu/index.html) and the TCGA dataset [15]. UALCAN is an online portal containing clinical data of 31 cancer types and cancer OMICS data such as TCGA, MET500, and CPTAC. Various kinds of analyses include relative expression of the specific gene among normal and cancer tissues/cells according to age, sex, body weight, race tumor grade, cancer stages, and survivability rate, etc. (http://ualcan.path.uab.edu/index.html).
All the genes positively correlated with NRP1 and ACE2 in both KIPC and KIRP were downloaded from the TCGA dataset of the UALCAN and processed and viewed by FunRich software (http://funrich.org/index.html) and InteractiVenn (http://www.interactivenn.net/) [16,17]. The FunRich (Functional Enrichment) analysis tool is designed for customized handling and analysis of the datasets of various proteins and genes for graphical depiction.
A total of 7703 genes that are reported to be associated with COVID-19 were extracted from the Comparative Toxicogenomics Database (CTD) and processed (http://ctdbase.org/) [18]. CTD provides information about the interaction of genes/proteins and chemicals and the relationship of disease and genes/proteins and chemicals, thereby helping to make a possible hypothesis on the disease mechanisms. These genes are associated with COVID-19 and are either involved directly in the disease mechanism, or a therapeutic target, or have a chemical interaction. For the relationship among the genes associated with NRP1, ACE2, and COVID-19, a coexpression analysis was conducted and visualized using InteractiVenn (http://www.interactivenn.net/) [16,17]. It is an online-based tool used to analyze the dataset in the form of Venn diagrams.

3. Results and Discussion

KIRC and KIRP are the commonest type of kidney cancers and might cover up to 90% and 10% of the total renal cell carcinoma cases, respectively [19,20,21]. Adults, compared to children, are more susceptible to KIRC, and immune-related genes (IRGs) play a vital role in the development of this type of cancer [19]. However, both KIRC and KIRP may coexist in the same kidney [22]. Many reports showed that SARS-CoV-2 might cause direct kidney injury due to the high expression of ACE2 in the renal tissue, and multiple factors such as endothelial cell injury, host immune clearance, and immune tolerance disorders, and lipid metabolic disorders, etc. promote kidney injury [7,23,24]. Previous reports also suggested that the newly identified SARS-CoV-2 host factor NRP1 mRNA and protein expression in the kidney also control the integrity of the glomerular basement membrane [25,26]. A recent study demonstrated that high expression of NRP1 upregulates SARS-CoV-2 infections [6]. In the present study, the NRP1 expression in thirty-three (33) human cancers was checked using the GEPIA2 server [14]. Interestingly, the highest level of expression of NRP1 was detected in KIRC among all 33 human cancers (Figure 1).
Though increased NRP1 expression was observed both in KIRC and KIRP compared to healthy conditions, the expression of NRP1 was found to be significantly upregulated in KIRC compared to healthy humans as measured using the TCGA dataset of UALCAN (Figure 2A,B). In addition, ACE2 expression in KIRC and KIRP was significantly upregulated compared to healthy conditions (Figure 2CD). The findings of our investigation were further supported by Tripathi et al., who analyzed the RNA-Seq data of various organs from the TCGA and GTsX databases, revealing that patients with renal carcinoma are expected to be at higher risk of SARS-CoV-2 infection [27]. Another study also revealed that renal carcinomas are reported to be associated with an increased risk of coronavirus infection due to the immune-modulating role of ACE2 in renal cancers [27]. Therefore, these results suggest that, along with the ACE2 expression, NRP1 expression might be involved in renal failure due to SARS-CoV-2 in renal cancer patients.
The survivability rate of renal cancer patients depends on the treatment and metastatic condition. In addition, renal cell carcinoma may progress in COVID-19 patients, and the mortality rate is significantly higher than in non-cancer patients [13]. Accordingly, the survivability rate is significantly correlated with expressions of NRP1 and ACE2 in KIRC patients (Figure 3A,C).
Many host genes are expressed due to the SARS-CoV-2 infection, and expression variations of these genes regulate immune and other cell signaling pathways; therefore, they are involved in COVID-19 pathogenesis, disease progression, and case fatality [28]. A total of 7703 genes are reported to be associated with COVID-19 according to the Comparative Toxicogenomics Database (CTD), among which 128 genes have been overlapped with the genes positively expressed with both ACE2 and NRP1 in both KIRC and KIRP (Table 1 and Figure 4). The coexpression of many genes in COVID-19, KIRC, and KIRP concerning ACE2 and NRP1 expression might be involved in molecular mechanisms of direct kidney injury by SARS-CoV-2, cancer progression, and high mortality of renal carcinoma associated with COVID-19 patients. For example, JAK1 is one of the important pro-inflammatory cytokines that plays a role in COVID-19 pathogenesis and renal cell carcinoma (RCC), and therefore the JAK-STAT pathway is suggested as a potential target for both COVID-19 and RCC patients [29,30,31]. Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) is associated with signal transduction involved in kidney pathogenesis by regulating inflammation and oxidative stress [32]. TRAF6 also plays a vital role in COVID-19 pathogenesis through various cell-signaling pathways [33]. Activating transcription factor 2 (ATF2) highly expresses in RCC and regulates the transcription of CyclinB1, CyclinD1, Snail, and Vimentin and acts as a poor prognostic biomarker [34]. The expression of ATF2 is also upregulated by the SARS-CoV N protein [35].
Surprisingly, it was revealed that both the VEGF (VEGFA, VEGFC, and VEGFD) and HGF, binding proteins of NRP1, are also associated with COVID-19 [3]. Clinical studies reported that VEGF-D and HGF levels were significantly higher in the critical patients’ group, and these act as potential biomarkers of COVID-19 progression [36,37]. The elevated level of VEGF-D might be one of the important factors of blood clotting in COVID-19 patients, suggesting a therapeutic target [36,38]. Therefore, it might be suggested that a high expression of NRP1 along with ACE2 in renal carcinomas might be involved in COVID-19 pathogenesis.

4. Summary and Conclusions

The newly identified SARS-CoV-2 host factors, NRP1 and ACE2, are significantly upregulated in renal carcinomas. The expression of these factors is also correlated with the survivability of patients suffering from renal carcinomas. In addition, a large number of COVID-19-associated genes are coexpressed with the genes positively correlated with ACE2 and NRP1 in renal carcinomas. Therefore, along with the ACE2, a high expression of the newly identified host factor NRP1 in renal carcinomas may play a vital role in the increased risk of SARS-CoV-2 infection and high mortality of COVID-19 patients suffering from kidney cancers. The findings of this bioinformatic-based investigation will be helpful for further molecular studies and prevention and/or treatment strategies for COVID-19 patients associated with renal carcinomas.

Author Contributions

M.G.H. designed the study, extracted and analyzed the data, and wrote the manuscript. M.G.H., S.A., and M.J.U. edited, revised, and approved the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This study has not been supported by any research grant.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All the data and materials used in this study have been mentioned in the article.

Conflicts of Interest

The authors declare no competing interest.

References

  1. Gelfand, M.V.; Hagan, N.; Tata, A.; Oh, W.-J.; Lacoste, B.; Kang, K.-T.; Kopycinska, J.; Bischoff, J.; Wang, J.-H.; Gu, C. Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. Elife 2014, 3, e03720. [Google Scholar] [CrossRef] [Scilit]
  2. Mamluk, R.; Gechtman, Z.; Kutcher, M.E.; Gasiunas, N.; Gallagher, J.; Klagsbrun, M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J. Biol. Chem. 2002, 277, 24818–24825. [Google Scholar] [CrossRef] [Scilit]
  3. Sulpice, E.; Plouët, J.; Bergé, M.; Allanic, D.; Tobelem, G.; Merkulova-Rainon, T. Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 2008, 111, 2036–2045. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Koitka, A.; Cooper, M.E.; Thomas, M.C.; Tikellis, C. Angiotensin converting enzyme 2 in the kidney. Clin. Exp. Pharmacol. Physiol. 2008, 35, 420–425. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Mizuiri, S.; Ohashi, Y. ACE and ACE2 in kidney disease. World J. Nephrol. 2015, 4, 74–82. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Daly, J.L.; Simonetti, B.; Klein, K.; Chen, K.E.; Williamson, M.K.; Antón-Plágaro, C.; Shoemark, D.K.; Simón-Gracia, L.; Bauer, M.; Hollandi, R.; et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 2020, 370, 861–865. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Rahman, M.D.; Zahan, S.; Al Hasib, T.; Ahmed, K.; Khanam, M.; Omit, S.; Moni, A.; Uddin, M.J. Current knowledge on mechanisms involved in SARS-CoV-2 infection and kidney diseases. J. Adv. Biotechnol. Exp. Ther. 2020, 3, 30–35. [Google Scholar] [CrossRef] [Scilit]
  8. Robba, C.; Battaglini, D.; Pelosi, P.; Rocco, P.R.M. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev. Respir. Med. 2020, 14, 865–868. [Google Scholar] [CrossRef] [Scilit]
  9. Hossain, M.G.; Akter, S.; Uddin, M.J. Expression Profile of SARS-COV-2 Entry Receptor ACE2 in the Hepatocellular Carcinoma and its Impact on COVID-19 Patients. J. Microbiol. Biotechnol. Food Sci. 2021, e5140. [Google Scholar] [CrossRef]
  10. Cheng, Y.; Luo, R.; Wang, K.; Zhang, M.; Wang, Z.; Dong, L.; Li, J.; Yao, Y.; Ge, S.; Xu, G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020, 97, 829–838. [Google Scholar] [CrossRef] [Scilit]
  11. Portolés, J.; Marques, M.; López-Sánchez, P.; de Valdenebro, M.; Muñez, E.; Serrano, M.L.; Malo, R.; García, E.; Cuervas, V. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol. Dial. Transplant. 2020, 35, 1353–1361. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Fu, D.; Yang, B.; Xu, J.; Mao, Z.; Zhou, C.; Xue, C. COVID-19 Infection in a Patient with End-Stage Kidney Disease. Nephron 2020, 144, 245–247. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Tsimafeyeu, I.; Alekseeva, G.; Berkut, M.; Nosov, A.; Myslevtsev, I.; Andrianov, A.; Semenov, A.; Borisov, P.; Zukov, R.; Goutnik, V.; et al. COVID-19 in Patients with Renal Cell Carcinoma in the Russian Federation. Clin. Genitourin. Cancer 2021, 19, e69–e71. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Tang, Z.; Kang, B.; Li, C.; Chen, T.; Zhang, Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019, 47, W556–W560. [Google Scholar] [CrossRef] [Scilit]
  15. Chandrashekar, D.S.; Bashel, B.; Balasubramanya, S.A.H.; Creighton, C.J.; Ponce-Rodriguez, I.; Chakravarthi, B.V.S.K.; Varambally, S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 2017, 19, 649–658. [Google Scholar] [CrossRef] [Scilit]
  16. Heberle, H.; Meirelles, G.V.; da Silva, F.R.; Telles, G.P.; Minghim, R. InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. BMC Bioinform. 2015, 16, 169. [Google Scholar] [CrossRef] [Scilit]
  17. Pathan, M.; Keerthikumar, S.; Ang, C.S.; Gangoda, L.; Quek, C.Y.; Williamson, N.A.; Mouradov, D.; Sieber, O.M.; Simpson, R.J.; Salim, A.; et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics 2015, 15, 2597–2601. [Google Scholar] [CrossRef] [Scilit]
  18. Mattingly, C.J.; Colby, G.T.; Forrest, J.N.; Boyer, J.L. The Comparative Toxicogenomics Database (CTD). Environ. Health Perspect. 2003, 111, 793–795. [Google Scholar] [CrossRef] [Scilit]
  19. Wan, B.; Liu, B.; Huang, Y.; Yu, G.; Lv, C. Prognostic value of immune-related genes in clear cell renal cell carcinoma. Aging 2019, 11, 11474–11489. [Google Scholar] [CrossRef]
  20. Hsieh, J.J.; Purdue, M.P.; Signoretti, S.; Swanton, C.; Albiges, L.; Schmidinger, M.; Heng, D.Y.; Larkin, J.; Ficarra, V. Renal cell carcinoma. Nat. Rev. Dis. Primers 2017, 3, 17009. [Google Scholar] [CrossRef] [Scilit]
  21. Lan, H.; Zeng, J.; Chen, G.; Huang, H. Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization. Oncotarget 2017, 8, 110811–110829. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Ustuner, M.; Yaprak, B.; Teke, K.; Ciftci, S.; Kart, M.; Yildiz, K.; Culha, M. Coexisting papillary and clear renal cell carcinoma in the same kidney. Case Rep. Urol. 2014, 2014, 575181. [Google Scholar] [CrossRef] [Scilit]
  23. Wang, M.; Xiong, H.; Chen, H.; Li, Q.; Ruan, X.Z. Renal Injury by SARS-CoV-2 Infection: A Systematic Review. Kidney Dis. 2021, 7, 100–110. [Google Scholar] [CrossRef] [Scilit]
  24. Soleimani, M. Acute Kidney Injury in SARS-CoV-2 Infection: Direct Effect of Virus on Kidney Proximal Tubule Cells. Int. J. Mol. Sci. 2020, 21, 3275. [Google Scholar] [CrossRef] [Scilit]
  25. Wnuk, M.; Anderegg, M.A.; Graber, W.A.; Buergy, R.; Fuster, D.G.; Djonov, V. Neuropilin1 regulates glomerular function and basement membrane composition through pericytes in the mouse kidney. Kidney Int. 2017, 91, 868–879. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Schramek, H.; Sarközi, R.; Lauterberg, C.; Kronbichler, A.; Pirklbauer, M.; Albrecht, R.; Noppert, S.J.; Perco, P.; Rudnicki, M.; Strutz, F.M.; et al. Neuropilin-1 and neuropilin-2 are differentially expressed in human proteinuric nephropathies and cytokine-stimulated proximal tubular cells. Lab. Investig. A J. Tech. Methods Pathol. 2009, 89, 1304–1316. [Google Scholar] [CrossRef] [Scilit]
  27. Tripathi, S.C.; Deshmukh, V.; Creighton, C.J.; Patil, A. Renal Carcinoma Is Associated with Increased Risk of Coronavirus Infections. Front. Mol. Biosci. 2020, 7, 579422. [Google Scholar] [CrossRef] [Scilit]
  28. Khan, M.A.; Islam, A. SARS-CoV-2 Proteins Exploit Host’s Genetic and Epigenetic Mediators for the Annexation of Key Host Signaling Pathways. Front. Mol. Biosci. 2020, 7, 598583. [Google Scholar] [CrossRef] [Scilit]
  29. Spinelli, F.R.; Colbert, R.A.; Gadina, M. JAK1: Number one in the family; number one in inflammation? Rheumatology 2021, 60, ii3–ii10. [Google Scholar] [CrossRef] [Scilit]
  30. Shang, D.; Liu, Y.; Ito, N.; Kamoto, T.; Ogawa, O. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance. Cancer Sci. 2007, 98, 1259–1264. [Google Scholar] [CrossRef] [Scilit]
  31. Seif, F.; Aazami, H.; Khoshmirsafa, M.; Kamali, M.; Mohsenzadegan, M.; Pornour, M.; Mansouri, D. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Int. Arch. Allergy Immunol. 2020, 181, 467–475. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Chen, X.; Zhao, Y.; Xu, J.; Bao, J.; Zhao, J.; Chen, J.; Chen, G.; Han, J. The Nephroprotective Effect of TNF Receptor-Associated Factor 6 (TRAF6) Blockade on LPS-Induced Acute Renal Injury Through the Inhibition if Inflammation and Oxidative Stress. Med. Sci. Monit. 2020, 26, e919698. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Aboudounya, M.M.; Heads, R.J. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation. Mediat. Inflamm. 2021, 2021, 8874339. [Google Scholar] [CrossRef] [Scilit]
  34. Wu, D.S.; Chen, C.; Wu, Z.J.; Liu, B.; Gao, L.; Yang, Q.; Chen, W.; Chen, J.M.; Bao, Y.; Qu, L.; et al. ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma. J. Exp. Clin. Cancer Res. CR 2016, 35, 108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. He, R.; Leeson, A.; Andonov, A.; Li, Y.; Bastien, N.; Cao, J.; Osiowy, C.; Dobie, F.; Cutts, T.; Ballantine, M.; et al. Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. Biochem. Biophys. Res. Commun. 2003, 311, 870–876. [Google Scholar] [CrossRef] [Scilit]
  36. Kong, Y.; Han, J.; Wu, X.; Zeng, H.; Liu, J.; Zhang, H. VEGF-D: A novel biomarker for detection of COVID-19 progression. Crit. Care 2020, 24, 373. [Google Scholar] [CrossRef] [Scilit]
  37. Tamayo-Velasco, Á.; Martínez-Paz, P.; Peñarrubia-Ponce, M.J.; de la Fuente, I.; Pérez-González, S.; Fernández, I.; Dueñas, C.; Gómez-Sánchez, E.; Lorenzo-López, M.; Gómez-Pesquera, E.; et al. HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. J. Clin. Med. 2021, 10, 2017. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Yin, X.X.; Zheng, X.R.; Peng, W.; Wu, M.L.; Mao, X.Y. Vascular Endothelial Growth Factor (VEGF) as a Vital Target for Brain Inflammation during the COVID-19 Outbreak. ACS Chem. Neurosci. 2020, 11, 1704–1705. [Google Scholar] [CrossRef] [Scilit]
Idr 13 00081 g001
Figure 1. NRP1 expression profile across all tumor samples and paired normal tissues (dot plot). Each dot represents the expression of samples. T means tumor and N means normal.
Figure 1. NRP1 expression profile across all tumor samples and paired normal tissues (dot plot). Each dot represents the expression of samples. T means tumor and N means normal.
Idr 13 00081 g001
Idr 13 00081 g002
Figure 2. NRP1 and ACE2 mRNA expression profile in renal cancer analyzed from UALCAN. (A,B) Expression of NRP1in KIRC and KIRP. (C,D) Expression profile of ACE2 in KIRC and KIRP. The threshold p-values: * < 0.05, ** < 0.01, *** < 0.001, and **** < 0.0001. KIRC, KIRP, and TCGA stand for kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, and The Cancer Genome Atlas, respectively.
Figure 2. NRP1 and ACE2 mRNA expression profile in renal cancer analyzed from UALCAN. (A,B) Expression of NRP1in KIRC and KIRP. (C,D) Expression profile of ACE2 in KIRC and KIRP. The threshold p-values: * < 0.05, ** < 0.01, *** < 0.001, and **** < 0.0001. KIRC, KIRP, and TCGA stand for kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, and The Cancer Genome Atlas, respectively.
Idr 13 00081 g002
Idr 13 00081 g003
Figure 3. Relationship between NRP1 and ACE2 expression in renal cancer and patient’s survivability. (A) Effect of NRP1 expression level on KIRC patient survival. (B) Effect of NRP1 expression level on KIRP patient survival. (C) Effect of ACE2 expression level on KIRC patient survival. (D) Effect of ACE2 expression level on KIRP patient survival. The threshold p-value indicates the statistical significance. KIRC, KIRP, and TCGA stand for kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, and The Cancer Genome Atlas, respectively.
Figure 3. Relationship between NRP1 and ACE2 expression in renal cancer and patient’s survivability. (A) Effect of NRP1 expression level on KIRC patient survival. (B) Effect of NRP1 expression level on KIRP patient survival. (C) Effect of ACE2 expression level on KIRC patient survival. (D) Effect of ACE2 expression level on KIRP patient survival. The threshold p-value indicates the statistical significance. KIRC, KIRP, and TCGA stand for kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, and The Cancer Genome Atlas, respectively.
Idr 13 00081 g003
Idr 13 00081 g004
Figure 4. Coexpression analysis of genes involved in COVID-19, KIRC, and KIRP concerning NRP1 and ACE2 expression profiles. The indicated genes were downloaded from the databases mentioned in the Methods section, and coexpression analysis was conducted and visualized using InteractiVenn (http://www.interactivenn.net/).
Figure 4. Coexpression analysis of genes involved in COVID-19, KIRC, and KIRP concerning NRP1 and ACE2 expression profiles. The indicated genes were downloaded from the databases mentioned in the Methods section, and coexpression analysis was conducted and visualized using InteractiVenn (http://www.interactivenn.net/).
Idr 13 00081 g004
Table 1. List of 128 coexpressed genes in COVID-19, KIRC, and KIRP concerning NRP1 and ACE2 expression profiles.
Table 1. List of 128 coexpressed genes in COVID-19, KIRC, and KIRP concerning NRP1 and ACE2 expression profiles.
Sl.GeneSl.GeneSl.GeneSl.GeneSl.Gene
1.ATF227.ATP7B53.SLC35A579.SLC33A1105.DYNLL2
2.CYLD28.SLC40A154.BBS1080.WDR31106.PCYOX1
3.HBP129.ALAD55.MED2981.SIK2107.APPL2
4.PGK130.RNF19B56.AP3B182.TCP11L1108.CDC14B
5.CFLAR31.RAG157.TBC1D1983.RAB3IP109.DBT
6.CHUK32.IFIH158.KBTBD384.USP8110.HFE
7.RAB7A33.TAOK359.TULP385.DAZAP2111.MYO6
8.SLC30A434.APPL160.AASDHPPT86.DDX18112.AKTIP
9.ACOX135.TGOLN261.TGFBRAP187.PEX12113.AFF4
10.TEAD136.CANX62.CRIPT88.DUSP11114.RIOK3
11.MTMR637.WIPF263.TM9SF289.SBNO1115.RRAGC
12.PPP2R1B38.STOM64.RAB2190.VPS33A116.RNF13
13.RAB1A39.PNMA265.MAGT191.FBXO3117.IDE
14.NCOA440.TSR166.ANKRD2792.SAP30L118.PAFAH1B1
15.AP1G141.MAP3K1367.DHX2993.MTRR119.ENDOD1
16.JAK142.PIGN68.DENND5B94.RANBP2120.CLTC
17.ATF7IP43.APBB169.TMLHE95.EPB41L4A121.PHLDB2
18.MIA244.PSMD1170.BIRC296.NLRX1122.FZD1
19.TSHZ145.VPS2471.DCTN197.SGCB123.CREB5
20.SPAG946.TBL1X72.NARS298.ZFP91124.ADD3
21.MLEC47.AP2B173.SHPK99.FARS2125.SLC1A1
22.TRAF648.INVS74.TTC26100.PURA126.PPP2CA
23.IFIT149.NCOA175.SLU7101.FRMD4B127.APC
24.RPS6KA350.PIK3R476.TXNDC9102.MDM1128.NCOR1
25.FTO51.TMEM12777.CHIC1103.PCBP1
26.CLIC452.TTC21B78.ZSWIM5104.BICC1
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hossain, M.G.; Akter, S.; Uddin, M.J. Emerging Role of Neuropilin-1 and Angiotensin-Converting Enzyme-2 in Renal Carcinoma-Associated COVID-19 Pathogenesis. Infect. Dis. Rep. 2021, 13, 902-909. https://doi.org/10.3390/idr13040081

AMA Style

Hossain MG, Akter S, Uddin MJ. Emerging Role of Neuropilin-1 and Angiotensin-Converting Enzyme-2 in Renal Carcinoma-Associated COVID-19 Pathogenesis. Infectious Disease Reports. 2021; 13(4):902-909. https://doi.org/10.3390/idr13040081

Chicago/Turabian Style

Hossain, Md. Golzar, Sharmin Akter, and Md Jamal Uddin. 2021. "Emerging Role of Neuropilin-1 and Angiotensin-Converting Enzyme-2 in Renal Carcinoma-Associated COVID-19 Pathogenesis" Infectious Disease Reports 13, no. 4: 902-909. https://doi.org/10.3390/idr13040081

APA Style

Hossain, M. G., Akter, S., & Uddin, M. J. (2021). Emerging Role of Neuropilin-1 and Angiotensin-Converting Enzyme-2 in Renal Carcinoma-Associated COVID-19 Pathogenesis. Infectious Disease Reports, 13(4), 902-909. https://doi.org/10.3390/idr13040081

Article Metrics

Back to TopTop